DYRK Inhibitor

DYRK Inhibitors (40):

Cat. No.	Product Name	Effect	Purity

HY-100464

tBID	Inhibitor	98.24%
tBID is a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2) with an IC₅₀ of 0.33 μM.

HY-111380

EHT 1610	Inhibitor	98.93%
EHT 1610 is a potent inhibitor of DYRK, with IC₅₀s of 0.36 nM (DYRK1A), 0.59 nM (DYRK1B), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis^-.

HY-15838

ID-8	Inhibitor	99.21%
ID-8 is an inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase (DYRK). ID-8 sustains embryonic stem cell (ESC) self-renewal and pluripotency. ID-8 enhances Wnt-mediated hESC survival and proliferation via inhibition of DYRKs.

HY-155723

Leucettinib-92	Inhibitor	98.54%
Leucettinib-92 (compound 92) is an inhibitor of DYRK/CLK kinase, The IC₅₀s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. 1.0 μM (DYRK3), 0.52 μM (DYRK4), 2.78 μM (GSK3).

HY-144290

ARN25068	Inhibitor	98.19%
ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation.

HY-179538

CSH-4044	Inhibitor
CSH-4044 can be isolated from fermented wheat germ extract. CSH-4044 is a unique benzothiazole compound. CSH-4044 can inhibit PIM3-driven BAD phosphorylation in pancreatic cancer cell lines as well as reducing DYRK1A-induced Tau phosphorylation in neuronal cells.

HY-180574

TSL2109	Inhibitor
TSL2109 is an orally active and selective DYRK2 and CDK4/6 inhibitor with an IC₅₀ value of 22 nM for DYRK2. TSL2109 exhibits high kinase selectivity over 93%. TSL2109 arrests cell cycle and induces apoptosis in virto. TSL2109 effectively overcomes Enzalutamide (HY-70002) resistance by suppressing tumor growth in vivo and virto. TSL2109 also shows CDK4/6 inhibitor resistance.TSL2109 demonstrates safety profile. TSL2109 can be used for prostate cancer research and breast cancer^[1][2].

HY-147060

Dyrk1A-IN-3	Inhibitor	99.68%
Dyrk1A-IN-3 (Compound 8b), a highly selective dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor, maintains high levels of DYRK1A binding affinity (IC₅₀=76 nM). Dyrk1A-IN-3 can be used for the research of neurodegenerative disorders such as Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease.

HY-128439

BT173	Inhibitor	98.71%
BT173 is a potent homeodomain interacting protein kinase 2 (HIPK2) inhibitor. BT173 binds to HIPK2 and does not inhibit HIPK2 kinase activity but rather, interfered allosterically with the ability of HIPK2 to associate with Smad3. BT173 attenuates renal fibrosis through suppression of the TGF-β1/Smad3 pathway. BT173 can be studied in research for kidney diseases such as renal fibrosis.

HY-N0737AG

Harmine (GMP)	Inhibitor
Harmine (GMP) (Telepathine (GMP)) is Harmine (HY-N0737A) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT_2A serotonin receptor, with an K_i of 397 nM.

HY-RS04095

Dyrk1a Mouse Pre-designed siRNA Set A	Inhibitor
Dyrk1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dyrk1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-U00439

Protein kinase inhibitor 1	Inhibitor	≥99.0%
Protein kinase inhibitor 1 is a novel inhibitor of HIPK2 with an IC₅₀ of 74 nM and K_d of 9.5 nM.

HY-117608

ML 315	Inhibitor
ML 315 is a selective dual inhibitor of CDK and DYRK with IC₅₀s of 68 nM and 282 nM, respectively. ML 315 is used in cancer and neurological disease research.

HY-117608A

ML 315 hydrochloride	Inhibitor	98.75%
ML 315 is a selective dual inhibitor of CDK and DYRK with IC₅₀s of 68 nM and 282 nM, respectively. ML 315 is used in cancer and neurological disease research.

HY-122665A

HTH-01-091 TFA	Inhibitor	99.48%
HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC₅₀ of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 TFA can be uesd for breast cancer research.

HY-RS04101

DYRK3 Human Pre-designed siRNA Set A	Inhibitor
DYRK3 Human Pre-designed siRNA Set A contains three designed siRNAs for DYRK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS04096

Dyrk1a Rat Pre-designed siRNA Set A	Inhibitor
Dyrk1a Rat Pre-designed siRNA Set A contains three designed siRNAs for Dyrk1a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-125202

KuWal151	Inhibitor
KuWal151 is a CLK1, CLK2 and CLK4 inhibitor with a high selectivity margin towards DYRK kinases. KuWal151 has potent antiproliferative activity in an array of cultured cancer cell lines.

HY-RS04099

Dyrk2 Mouse Pre-designed siRNA Set A	Inhibitor
Dyrk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dyrk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-161014

DYRK2-IN-1	Inhibitor
DYRK2-IN-1 (Compd 54) is an orally bioavailable DYRK2 inhibitor, with an IC₅₀ of 14 nM. DYRK2-IN-1 (Compd 54) can be used in the study of prostate cancer.

Name
Email *

	Sorry, but the email address you supplied was invalid.